Feed

VKTX

Viking Therapeutics

VKTX · NASDAQ

$41.65 -0.26% (-$0.11)

1M +22.93%

Market Cap $4.77B

P/E Ratio -

Div. Yield -

ROE 94.56%

Bulios Fair Price

$21.17

49.2% downside

Trenutna cena

$41.65

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica VKTX trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Odkleni pošteno ceno

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak

1/9

Valuation

0 /100

Expensive

P/B 11.67x

P/E N/A

EV/EBITDA N/A

Growth

100 /100

Growing

Book val. growth 63.83%

EPS growth N/A

Rev. growth N/A

Profitability

N/A

Gross margin N/A

Net margin N/A

Op. margin N/A

Quality

0 /100

Poor

ROIC 135.80%

ROE 94.56%

ROA 102.47%

Debt

69 /100

Low

Debt/Equity 0.01x

Current ratio 4.72x

Int. coverage -66,848.50x

Stability

37 /100

Moderate

Beta 0.68x

EPS volatility 120.52%

Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o VKTX

Online

O podjetju

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Brian Lian

Employees

Headquarters

San Diego

Prihajajoči dogodki

28 OKT.

Earnings

Upcoming earnings report

35d

⌘ K

StockBot Live

Tržne razmere Wall Street

Nasdaq dosegel rekord ob rasti tehnološkega sektorja

Nasdaq +0.45% rekordno ob rasti čipov. S&P 500 -0.01% nespremenjen, Dow -0.36% pa je upadel.

Vprašajte o tem

StockBot pozna 80,000+ delnic po vsem svetu